Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma

20260 citationsJournal Articlegold Open Access

Authors

Fumihiro Ito · Gifu Prefectural Tajimi Hospital

Koki Kobayashi · Gifu Prefectural Tajimi Hospital

Gaku Hayashi · Gifu Prefectural Tajimi Hospital

Shunsuke Kamijo · Gifu Prefectural Tajimi Hospital

Takashi Fujita · Gifu Prefectural Tajimi Hospital

Abstract

Durable remission with pembrolizumab following progression on avelumab suggests that switching from PD-L1 to PD-1 blockade can overcome resistance in selected patients; prospective studies and biomarker strategies, including PD-L2 assessment, are warranted and may guide individualized rechallenge strategies.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Nonmelanoma Skin Cancer Studies

Command Palette

Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma

Authors

Abstract

Topics & Keywords

Publication Details